Enanta Pharmaceuticals | ENTA - Loan Capital


Enanta Pharmaceuticals reported $0 in Loan Capital for its fiscal quarter ending in December of 2024.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Amgen USD 51.89B 1.88B Mar/2026
Arrowhead Research USD 538.1M 323.22M Dec/2025
AstraZeneca USD 25.96B 177M Mar/2026
BioCryst Pharmaceuticals USD 428.67M 234.31M Dec/2025
Biogen USD 6.29B 1.7M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
Gilead Sciences USD 22.13B 6M Dec/2025
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Halozyme Therapeutics USD 2.14B 1.34B Dec/2025
Heron Therapeutics USD 140.64M 975K Dec/2025
Immunic USD 0 0 Jun/2024
Incyte USD 29.41M 785K Mar/2026
Insmed USD 540.96M 1.24M Dec/2025
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
J&J USD 37.53B 1.91B Mar/2026
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
Ligand Pharmaceuticals USD 445.49M 445.44M Sep/2025
Merck USD 46.67B 77M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.45B 7.86B Mar/2026
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025